Schering: Competitor Switch Of Rx Antihistamine, Nasal Steroid Anticipated
This article was originally published in The Tan Sheet
Executive Summary
Schering-Plough expects the over-the-counter switch or generic availability of a competing Rx antihistamine or nasal steroid to impact its 2004 fiscal year earnings
You may also be interested in...
S&P ratings
Rating agency downgrades Schering-Plough's corporate credit and senior unsecured debt ratings from "A" to "A-," as well as its short-term corporate credit and commercial paper rating from "A-2" to "A-1." The negative outlook reflects uncertainty over Schering's earnings potential and the length of its ongoing corporate turnaround. Schering recently announced it expects 2004 operating losses to be worse than 2003 (1"The Tan Sheet" Feb. 2, 2004, p. 3)...
Glaxo’s Garnier Rebuts Schering Prediction On Flonase Switch
GlaxoSmithKline CEO Jean-Pierre Garnier called premature a prediction by Schering-Plough CEO Fred Hassan that FDA could approve a nasal-inhaled steroid for over-the-counter use this year
Allegra Faces Increasing Challenges In Rx Drug Arena
Obstacles to marketing second generation, non-sedating antihistamine Allegra effectively as a prescription drug have escalated substantially in the past year, according to Aventis